Allogeneic hematopoietic cell transplantation in a dog with acute large granular lymphocytic leukemia

Suter, Steven E.; Hamilton, Matthew J.; Sullivan, Edmund W.; Venkataraman, Gopalakrishnan M.

doi:10.2460/javma.246.9.994

Cited by 13 publications

(11 citation statements)

References 24 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies performed in the last years on hematopoietic stem cells from canine bone marrow. (Osgood et al 1939, Thomas et al 1962, Epstein et al 1967, Escobar et al 2012, Killian et al 2013, Sato et al 2013, Mathes et al 2014, Vrecenak et al 2014, Rosinski et al 2015, Suter et al 2015, Luangphakdy et al 2016, Lange et al 2017 Fig.2. Studies performed in the last years on mesenchymal stem cells from canine bone marrow.…”

Section: Topic Of General Interestmentioning

confidence: 99%

Bone marrow stem cell applied in the canine veterinary clinics

Gomes

Oliveira²,

Pinheiro

et al. 2017

Pesq. Vet. Bras.

View full text Add to dashboard Cite

Cell therapy represents an old therapeutic practice initiated with the transfusion of whole blood in different clinical situations. There is now a breakthrough in the study of multipotent stem cell therapy because of its functionality in regeneration of tissues, which promotes attention of the scientific community. Bone marrow is one of the main sources of multipotent stem cells, composed by hematopoietic stem cells responsible for the renewal of the cellular components of the blood, and mesenchymal stem cells that aid in the regeneration of tissues. These cells have a strong potential for the treatment of several diseases, due their main characteristics such as high plasticity, capacity for self-renewal and immunomodulation. Although, there are many studies that show good results with the use of cell therapy as a form of treatment for several diseases, some studies still show inconclusive or unsatisfactory results. Therefore, the objective of this study was to review the application of bone marrow stem cells in the canine model since improvements on the knowledge of the technique are necessary to enable its applicability with safety and efficacy.

show abstract

Section: Topic Of General Interestmentioning

confidence: 99%

Bone marrow stem cell applied in the canine veterinary clinics

Gomes

Oliveira²,

Pinheiro

et al. 2017

Pesq. Vet. Bras.

View full text Add to dashboard Cite

show abstract

“…Treatment was initiated on a modified CHOP chemotherapy protocol (cyclophosphamide, doxorubicin, vincristine, and prednisone). Dog leukocyte antigen (DLA) typing and matching was initiated on related relatives, similar to previously published studies 8 . After achievement of both molecular and complete clinical remission, the dog presented to our specialty hospital for transplantation.…”

Section: Case Summarymentioning

confidence: 90%

“…Immediately after the second fraction, related DLA‐matched previously‐harvested allogeneic hematopoietic stem cells (CD34+) were administered at 5.98 × 10 6 cells/kg IV over 30 minutes. The cells were obtained from the donor dog using a cell separator machine described in previous studies 8 . The patient was pretreated with diphenhydramine (Benadryl, Pfizer, Karlsruhe, Germany) and moved into reverse isolation.…”

Section: Case Summarymentioning

confidence: 99%

Acquired factor V inhibitors after allogeneic hematopoietic stem cell transplantation in a dog

Masciana

Peterson

Chretin

2020

Veterinary Internal Medicne

View full text Add to dashboard Cite

Objective: Describe the clinical course and management of a dog that underwent hematopoietic stem cell transplantation (HSCT) for treatment of B-cell lymphoma and developed acquired circulating factor V (FV) inhibitors. Case Summary: An 8-year-old male castrated Briard dog diagnosed with lymphoma (IVb, B-cell) presented for allogeneic HSCT. Despite multiple platelet, fresh frozen plasma, and red blood cell transfusions prolonged recovery and clinical bleeding occurred. Circulating acquired FV inhibitors were identified and hemorrhage subsequently was managed by immunosuppression. The dog was discharged when clinical resolution of bleeding was achieved. New or Unique Information Provided: This case report describes a dog undergoing curative intent treatment for lymphoma, and subsequently acquiring factor inhibition, and was successfully managed. Specific coagulation screening to assess for coagulation factor deficiencies or inhibitors is essential in the diagnosis and treatment of patients with refractory bleeding or only transient response to blood transfusion.

show abstract

“…An extended distance setup was chosen to allow low dose rate administration of TBI as well as to allow dogs of all sizes to be treated with the same field size. A dose rate of <20 cGy/min was planned based on prior reports of normal dog and clinical patient tolerance, as well as increasing toxicity with higher dose rates . To achieve a dose rate as low as 7 cGy/min at the dog's isocenter, a treatment distance of 338 cm from the source to the isocenter was chosen (inverse square, (100/338) × 80 cGy/min (available machine output rate setting) = 7 cGy/min).…”

Section: Methodsmentioning

confidence: 99%

“…High‐dose (8‐12 Gy) TBI protocols are more common in modern veterinary medicine. The most common indications include eradicating the recipient's bone marrow in preparation for an autologous stem cell transplant (SCT) and immunosuppressing the recipient to decrease the chances of allogeneic SCT rejection …”

Section: Introductionmentioning

confidence: 99%

Implementation of total body photon irradiation as part of an institutional bone marrow transplant program for the treatment of canine lymphoma and leukemias

Gieger

Nolan

Roback

et al. 2019

Vet Radiology Ultrasound

Self Cite

View full text Add to dashboard Cite

A total body irradiation (TBI) protocol was developed to support a bone marrow transplant (BMT) program for the treatment of canine hematologic malignancies. The purpose of this prospective study is to describe implementation of the protocol and resultant dosimetry. Nongraphic manual treatment planning using 6 MV photons, isocentric delivery, 40 × 40 cm field size, wall-mounted lasers to verify positioning, a lucite beam spoiler (without use of bolus material), a dose rate of 8.75 cGy/min at patient isocenter, and a source-to-axis distance of 338 cm were used for TBI. A monitor unit calculation formula was derived using ion chamber measurements and a solid water phantom. Five thermoluminescent dosimeters (TLDs) were used at various anatomic locations in each of four cadaver dogs, to verify fidelity of the monitor unit formula prior to clinical implementation. In vivo dosimetric data were then collected with five TLDs at various anatomic locations in six patients treated with TBI. A total dose of 10 Gy divided into two 5 Gy fractions was delivered approximately 16 h apart, immediately followed by autologous stem cell transplant. The mean difference between prescribed and delivered doses ranged from 99% to 109% for various sites in cadavers, and from 83% to 121% in clinical patients. The mean total body dose in cadavers and clinical patients when whole body dose was estimated by averaging doses measured by variably placed TLDs ranged from 98% to 108% and 93% to 102% of the prescribed dose, respectively, which was considered acceptable. This protocol could be used for institutional implementation of TBI. K E Y W O R D Scadaver, lymphosarcoma, myeloablation, thermoluminescent dosimeter 1 586

show abstract

Allogeneic hematopoietic cell transplantation in a dog with acute large granular lymphocytic leukemia

Cited by 13 publications

References 24 publications

Bone marrow stem cell applied in the canine veterinary clinics

Bone marrow stem cell applied in the canine veterinary clinics

Acquired factor V inhibitors after allogeneic hematopoietic stem cell transplantation in a dog

Implementation of total body photon irradiation as part of an institutional bone marrow transplant program for the treatment of canine lymphoma and leukemias

Contact Info

Product

Resources

About